Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

Author： Rutten-van Mölken Maureen   Oostenbrink Jan   Miravitlles Marc   Monz Brigitta  

Publisher： Springer Publishing Company

ISSN： 1618-7598

Source： The European Journal of Health Economics, Vol.8, Iss.2, 2007-06, pp. : 123-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece

By Maniadakis Nikos   Tzanakis Nikolaos   Fragoulakis Vassilis   Hatzikou Magdalini   Siafakas Nikolaos  

Current Medical Research and Opinion, Vol. 22, Iss. 8, 2006-08 ,pp. : 1599-1607

Informa Healthcare

Access to resources Recommend Favorite

Tiotropium for the treatment of chronic obstructive pulmonary disease

By Tashkin Donald P  

Clinical Practice, Vol. 10, Iss. 2, 2013-03 ,pp. : 141-155

Future Medicine

Access to resources Recommend Favorite

Effects of Tiotropium and Salmeterol/Fluticasone Propionate on Airway Wall Thickness in Chronic Obstructive Pulmonary Disease

By  

Respiration, Vol. 86, Iss. 4, 2013-07 ,pp. : 280-287

Karger

Access to resources Recommend Favorite

Inhalation by Nebulization of Albuterol-Ipratropium Combination (Dey Combination) Is Superior to Either Agent Alone in the Treatment of Chronic Obstructive Pulmonary Disease

By  

Respiration, Vol. 65, Iss. 5, 1998-10 ,pp. : 354-362

Karger

Access to resources Recommend Favorite

The Effect of Tiotropium on Hyperinflation and Exercise Capacity in Chronic Obstructive Pulmonary Disease

By  

Respiration, Vol. 73, Iss. 4, 2006-07 ,pp. : 420-427

Karger

Access to resources Recommend Favorite